HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
Chaoju Eye Care preparing to re-enter acquisition mode?
The private hospital and clinic operator announced two new purchases, signaling a potential return to acquisitions after a quiet period last year Key Takeaways: Chaoju Eye Care announced plans to…
Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
So-Young rethinks reverse share split as its stock surges
The cosmetic surgery specialist’s shares have nearly doubled in the last two weeks as investors flock to its new business model centered on self-operated clinics Key Takeaways: So-Young has delayed…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Its revenue falling, Dazhong Dental looks to M&A to brighten its outlook
The company has filed to list in Hong Kong, aiming to jumpstart its falling revenue and profits by buying up rivals in China’s fragmented dental services market Key Takeaways: Dazhong…
Recent Articles
RELATED ARTICLES
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK -
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
